This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Natural ASA Announces Patent, Licensing Decisions


LYSAKER, NorwayNatural ASA entered into long-term licensing agreements with Cognis and Loders Croklaan for its conjugated linoleic acid (CLA) intellectual property. The agreement with Cognis grants exclusive rights for the production and sales of Tonalin®, Natural’s CLA trademark, on a worldwide basis. The exclusivity is in addition to Tonalin, based on Natural’s CLA technology, patents and licenses; the license agreement will run until 2018, with royalties based on sale of CLA/Tonalin.

Natural also entered into a long-term licensing agreement with Loders Croklaan/Lipid Nutrition for Clarinol™ CLA; the license agreement will run for the span of the patents and covers CLA in the dietary supplement market with royalty payments to Natural.

Natural ASA also reached a settlement agreement with ArkoPharma over a lawsuit filed by Natural in 2006 alleging infringement of the CLA patents. ArkoPharma is not contesting the assertions on infringement; it will pay compensation and, in the future, obtain CLA for use in dietary supplements only from Natural’s licensees.

“The strength of our patent portfolio should be a wake-up call for other possible parties involved in the production and sale of non-licensed CLA” said Jostein Dalland, managing director, Natural ASA ( “No companies can expect to derive benefits from the substantial investment that we have made in inventions connected with CLA without purchasing goods from one of Natural’s licensees: Cognis, Loders Croklaan/Lipid Nutrition or BASF. This is the core of patent law and the foundation for our investment in innovation and intellectual property rights.”

comments powered by Disqus